Abstract Library

#3002 Quality of Life, Tumour Heterogeneity and Biomarker Levels in Patients with Progressive Pancreatic or Midgut Neuroendocrine Tumours: Baseline Data from CLARINET FORTE

Introduction: Lanreotide autogel (LAN) 120 mg every (q)28 days (standard regimen) improves progression-free survival vs placebo in patients with advanced, somatostatin receptor-positive (SSTR+) gastroenteropancreatic neuroendocrine tumours (NETs).

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Ruszniewski P, Ćwikła J, Lombard-Bohas C, Borbath I, Shah T,

Keywords: Neuroendocrine tumours, lanreotide,

#2209 The ENETS Registry: First Results of a Collaborative Effort Including over 12.000 Patients with Neuroendocrine Neoplasms (NENs) from 7 European Countries

Introduction: NENs are rare and global European epidemiologic data are only based on national or compilation of national registries. So, there is a need for comprehensive homogenous information

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Borbath I

Authors: Borbath I, Pape U, Garcia-Carbonero R, Sedláčková E, Kollár A,

Keywords: ENETS registry, Europe,

#1813 Determination of an Optimal Response Cut-Off to Predict Progression-Free Survival(PFS) in Patients(pts) with Well-Differentiated Advanced Pancreatic Neuroendocrine Tumours(pNETs) Treated with Sunitinib(S): An Alternative to the Current RECIST-Response

Introduction: Sunitinib prolongs PFS in pNET; RECIST defined-partial responses (PR; ≥30% decrease) are low.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Lamarca A

Authors: Lamarca A, Barriuso J, Kulke M, Borbath I, Lenz H,

Keywords: sunitinib, RECIST, cut-off,

#1609 Prognostic Relevance of Pancreatic Neuroendocrine Tumors Grading on EUS-FNA

Introduction: Since WHO 2010, resected pNETs are graded as G1, G2 or G3 using the Ki67-LI. EUS-FNA is often used for diagnosis but few studies have assessed its value for grading.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Borbath I

Authors: Boutsen L, Borbath I, Van Maanen A, Mourin A, Weynand B,

Keywords: EUS-FNA, KI67, pNET, OS,

#1235 The Belgian DNET Registry: A Prospective, National, Web-Based Registry of Digestive Neuro-Endocrine Tumours (NET). Status After 2 Years of Inclusion.

Introduction: NET are rare neoplasms. The Belgian Group of Digestive Oncology created a web-based registry to have an overview on incidence, diagnosis and therapies performed in Belgian pts. The DNET registry was launched in 01/2012.

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author: Borbath I

Authors: Borbath I, Dresse D, Verslype C, Demolin G, Rezai Kalantari H,

Keywords: Registry, Belgium,